Celadon Pharmaceuticals

Executive Summary

Celadon Pharmaceuticals is a UK-based private company specializing in cannabis-derived medicines for neurological conditions and rare diseases. Founded in 2018, it operates a vertically integrated model with EU-GMP licensed cultivation and extraction facilities, producing high-THC active pharmaceutical ingredients. Its lead program targets chronic pain, leveraging proprietary formulations to address significant unmet needs. The company is positioned in a growing market for cannabinoid therapeutics but remains early-stage with no approved products or disclosed funding. Key risks include regulatory hurdles in the UK and EU, clinical trial execution, and competition from larger players. Despite limited public information, Celadon's focused strategy and manufacturing capabilities provide a foundation for potential value creation if clinical milestones are achieved.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 chronic pain trial40% success
• 2027Partnership with a major pharmaceutical company30% success
• TBDRegulatory submission for rare disease indication in EU25% success